The current NCCN guidelines have expanded the indication for EGFR and ALK testing to nonsquamous NSCLC and NSCLC not otherwise specified (NOS) as well as to nonsmokers with metastatic squamous cell carcinoma histotype, and recommend PD‐L1 TPS assessment at the initial diagnosis of advanced NSCLC.11 This evidence concerns the gene ALK and non-small cell lung carcinoma.